| Literature DB >> 29085965 |
Weijun Wei1,2, Emily B Ehlerding3, Xiaoli Lan4, Quanyong Luo5, Weibo Cai6,7,8.
Abstract
Melanoma represents the most aggressive form of skin cancer, and its incidence continues to rise worldwide. 18F-FDG PET imaging has transformed diagnostic nuclear medicine and has become an essential component in the management of melanoma, but still has its drawbacks. With the rapid growth in the field of nuclear medicine and molecular imaging, a variety of promising probes that enable early diagnosis and detection of melanoma have been developed. The substantial preclinical success of melanin- and peptide-based probes has recently resulted in the translation of several radiotracers to clinical settings for noninvasive imaging and treatment of melanoma in humans. In this review, we focus on the latest developments in radiolabeled molecular imaging probes for melanoma in preclinical and clinical settings, and discuss the challenges and opportunities for future development.Entities:
Keywords: Cancer; Immunotherapy; Melanoma; Molecular imaging; Positron emission tomography (PET); Single-photon emission computed tomography (SPECT); Theranostics
Mesh:
Substances:
Year: 2017 PMID: 29085965 PMCID: PMC5700861 DOI: 10.1007/s00259-017-3839-5
Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN: 1619-7070 Impact factor: 9.236